Neurogene Inc. (NGNE)

Neurogene Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	148.72	82.02	142.47	192.56	143.09
Short-Term Investments	48.95	0	0	0	0
Cash & Cash Equivalents	197.67	82.02	142.47	192.56	143.09
Cash Growth	140.99%	-42.43%	-26.01%	34.57%	86.01%
Other Current Assets	2.68	2.7	1.52	1.97	0.5
Total Current Assets	200.35	84.72	143.99	194.52	143.6
Property, Plant & Equipment	20.95	24.55	17.22	13.72	2.83
Goodwill and Intangibles	0	0	0.13	0.35	0.57
Other Long-Term Assets	1.27	0	1.93	1.93	0.03
Total Long-Term Assets	22.23	24.55	19.27	16	3.43
Total Assets	222.57	109.27	163.26	210.52	147.02
Accounts Payable	2.6	0.63	7.42	7.18	4.13
Current Debt	2.88	0.7	1.22	0.71	0.62
Other Current Liabilities	17.5	5.32	0	0	0
Total Current Liabilities	22.97	6.65	8.64	7.89	4.74
Long-Term Debt	13.37	3.99	11.76	11.41	0.59
Other Long-Term Liabilities	0.2	0	0	0	0
Total Long-Term Liabilities	13.58	3.99	11.76	11.41	0.59
Total Liabilities	36.55	10.64	20.4	19.3	5.34
Total Debt	16.26	4.69	12.98	12.12	1.21
Debt Growth	246.66%	-63.89%	7.11%	900.99%	7973.33%
Retained Earnings	-187.15	-150.84	-393.5	-332.81	-299.53
Shareholders' Equity	186.02	-145.74	142.86	191.22	141.69
Net Cash / Debt	181.41	77.33	129.48	180.43	141.88
Net Cash / Debt Growth	134.59%	-40.28%	-28.24%	27.17%	84.47%
Net Cash Per Share	38.95	196.01	47.05	69.63	104.98
Working Capital	177.38	78.07	135.35	186.63	138.85
Book Value Per Share	378.20	-369.40	51.91	73.79	104.83

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).